ArticleAdvances in immunology2016
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
Article in Advances in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.Nature communications · 2020Trial
- Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.British journal of cancer · 2017Trial
- Review
- Invariant Natural Killer T Cells in Cancer Immunotherapy: Lipid-Based Modulation, Nanotechnology, and Translational Advances.International journal of molecular sciences · 2026Review
- Article
- Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma.Molecular cancer therapeutics · 2025Article
- Review
- Development of a machine learning-based predictive risk model combining fatty acid metabolism and ferroptosis for immunotherapy response and prognosis in prostate cancer.Discover oncology · 2025Article
- First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trials.Therapeutic advances in medical oncology · 2025Article
- Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches.Frontiers in immunology · 2024Review
- Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors.Nature reviews. Clinical oncology · 2023Review
- Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators.Acta neuropathologica communications · 2023Review
- Extracellular Vesicles in Breast Cancer: From Biology and Function to Clinical Diagnosis and Therapeutic Management.International journal of molecular sciences · 2023Review
- Microbiome influencers of checkpoint blockade-associated toxicity.The Journal of experimental medicine · 2023Article
- Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer.Cancer medicine · 2022Article
- Intratumoral therapies and in-situ vaccination for melanoma.Human vaccines & immunotherapeutics · 2022Review
- The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor.Cancer immunology, immunotherapy : CII · 2022Article
- Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity.Cancers · 2022Review
- The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Despite recent clinical advances in immunotherapy, a fraction of cancer patients fails to respond to these interventions. Evidence from preclinical mouse models as well as clinical samples has provided evidence that the extent of activated T cell infiltration within the tumor microenvironment is associated with clinical response to immunotherapies including checkpoint blockade. Therefore, understanding the molecular mechanisms mediating the lack of T cell infiltration into the tumor microenvironment will be instrumental for the development of new therapeutic strategies to render those patients immunotherapy responsive. Recent data have suggested that major sources of intersubject heterogeneity include differences in somatic mutations in specific oncogene pathways between cancers of individual subjects and also environmental factors including commensal microbial composition. Successful identification of such causal factors should lead to new therapeutic approaches that may facilitate T cell entry into noninflamed tumors and expand the fraction of patients capable of responding to novel immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.